FindTrial
Sign In

TURBT

PROCEDURE11 trials

Sponsors

Spectrum Pharmaceuticals, Inc, Gregers G Hermann, National Cancer Institute (NCI), Tribhuvan University, Nepal, UroGen Pharma Ltd.

Conditions

Bladder CancerBladder NeoplasmBladder TumorsMuscle-invasive Bladder CancerNon-Muscle-Invasive Bladder CancerObturator Jerk in TURBTUrinary Bladder NeoplasmsUrothelial Carcinoma

Phase 1

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
CompletedNCT03258593
National Cancer Institute (NCI)Urinary Bladder Neoplasms
Start: 2018-06-07End: 2022-10-17Updated: 2026-08-25

Phase 3

Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)
CompletedNCT00461591
Spectrum Pharmaceuticals, IncBladder Cancer
Start: 2007-04-30End: 2012-01-31Updated: 2021-03-30
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)
CompletedNCT00598806
Spectrum Pharmaceuticals, IncBladder Cancer
Start: 2007-08-31End: 2012-01-31Updated: 2017-11-13
A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
TerminatedNCT04688931
UroGen Pharma Ltd.Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Start: 2021-02-19End: 2023-03-17Updated: 2024-06-06
HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer
Not yet recruitingNCT06327932
Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityNon-Muscle-Invasive Bladder Cancer
Start: 2024-04-01End: 2028-03-31Target: 320Updated: 2024-03-25

Unknown Phase

Laser Treatment of Bladder Tumors in the Outpatient Department
NCT02659332
Gregers G HermannBladder Tumors
Start: 2015-02-28End: 2016-06-30Target: 20Updated: 2016-01-21
Safety and Efficacy of Bipolar vs Monopolar Transurethral Resection of Bladder Tumor-A Randomized Controlled Trial
CompletedNCT04234165
Tribhuvan University, NepalObturator Jerk in TURBT
Start: 2017-05-01End: 2018-11-01Updated: 2020-01-21
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
RecruitingNCT04235764
National Cancer Institute (NCI)Bladder Cancer
Start: 2020-09-09End: 2027-09-30Target: 25Updated: 2026-09-08
Personalized Urine Biomarker for Patients With Bladder Cancer
NCT05467267
Ziv HospitalBladder Neoplasm
Start: 2022-08-31End: 2025-08-31Target: 20Updated: 2022-07-20
Multi-parametric MRI in Patients Suspected for Muscle Invasive Bladder Cancer: a New Local Staging Paradigm
RecruitingNCT05779631
Radboud University Medical CenterBladder Cancer, Muscle-invasive Bladder Cancer
Start: 2023-12-06End: 2031-06-30Target: 360Updated: 2026-01-08
Validity of Computed Tomography Versus Magnetic Resonance Imaging in Predicting Muscular Invasion of Bladder Cancer
NCT06046469
Menoufia UniversityBladder Cancer
Start: 2022-09-01End: 2024-03-01Target: 55Updated: 2023-09-21

Related Papers

Multiparametric MRI for local staging in patients with suspected muscle-invasive bladder cancer: study protocol for a multicentre, non-inferiority randomised controlled trial (the BladParadigm study)
BMJ Open2025-08-011 citations
Treatment of low-grade intermediate-risk non-muscle invasive bladder cancer with UGN-102: Results of the phase 3 ATLAS and ENVISION studies.
Journal of Clinical Oncology2025-05-281 citations
Treatment of low-grade intermediate-risk non-muscle-invasive bladder cancer with UGN-102: Results of the phase 3 ATLAS and ENVISION studies.
Journal of Clinical Oncology2025-02-10
MP16-20 FINAL RESULTS OF A PHASE I, SINGLE-ARM CLINICAL TRIAL OF THE COMBINATION OF DURVALUMAB AND VICINEUM IN BCG UNRESPONSIVE, HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER PATIENTS (NCT03258593)
The Journal of Urology2024-04-153 citations
PD48-09 A QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS OR TOXICITY (Q-TWIST) ANALYSIS OF SYSTEMIC THERAPY VERSUS STANDARD OF CARE INTRAVESICAL TREATMENT (BCG) IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS
The Journal of Urology2024-04-15
PD09-04 INTERIM ANALYSIS OF A PHASE I SINGLE-ARM STUDY OF THE COMBINATION OF DURVALUMAB (MEDI4736) AND VICINIUM (OPORTUZUMAB MONATOX, VB4-845) IN SUBJECTS WITH HIGH-GRADE NON-MUSCLE-INVASIVE BLADDER CANCER PREVIOUSLY TREATED WITH BACILLUS CALMETTE-GUERIN (BCG) (NCT03258593)
The Journal of Urology2021-08-045 citations